Natural history of hepatitis C virus among injecting drug users
Beld, M.G.H.M.

Citation for published version (APA):
Beld, M. G. H. M. (1999). Natural history of hepatitis C virus among injecting drug users

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)
### Contents

**Chapter 1**
- General introduction
- 1. History of hepatitis
- 2. The structural and functional organization of HCV
  - 2.1 The 5' untranslated region
  - 2.2 The core protein
  - 2.3 The envelope proteins E1 and E2
  - 2.4 The NS2 and NS3 proteins
  - 2.5 The NS4 region
  - 2.6 The NS5 region
  - 2.7 The 3' untranslated region
- 3. Prevalence of HCV
  - 3.1 General population
  - 3.2 Risk groups
- 4. Genetic heterogeneity: genotypes and quasispecies of HCV
- 5. Clinical profile of HCV infection
- 6. Host immune response to HCV
  - 6.1 Humoral immune response
  - 6.2 Cellular immune response
- 7. HCV RNA levels
  - 7.1 Profiles among patients not receiving antiviral-therapy
  - 7.2 Profiles among patients with antiviral-therapy

**Chapter 2**
Low levels of hepatitis C virus (HCV) RNA in serum, plasma, and peripheral blood mononuclear cells in injecting drug users during long antibody-undetectable periods prior to seroconversion
*Submitted to Blood*

**Chapter 3**
Different profiles of hepatitis C virus RNA loads following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels
*Journal of Clinical Microbiology, April 1998; 36:872-877*
Chapter 4
Quantitative antibody responses to structural (core) and non-structural (NS3, NS4, and NS5) hepatitis C virus (HCV) proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood
*Hepatology in press*

Chapter 5
Hepatitis C virus serotype-specific core and NS4 antibodies in injecting drug users participating in the Amsterdam cohort studies
*Journal of Clinical Microbiology, October 1998;36:3002-3006*

Chapter 6
Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters
*Virology 244, April 1998;4:872-877*

Chapter 7
Reduction of NS3 and NS5 antibodies to hepatitis C virus and increase in HCV RNA levels in HIV-coinfected injecting drug users
*Submitted to Journal of Infectious Diseases*

Chapter 8
General discussion

Chapter 9
Summary
Samenvatting
Publications
Nawoord